Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharma : Two Targets in Lilly Collaboration Meet Proof of Principle

11/12/2021 | 08:39am EST

By Chris Wack

Dicerna Pharmaceuticals Inc. said that Eli Lilly and Co. has declared proof of principle for the first two targets in the companies' exclusive relationship in neurodegeneration and pain therapies, under the companies' global research and licensing collaboration.

This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the company expects to receive in the fourth quarter.

"We are very pleased to announce Lilly's selection of two extrahepatic targets for advancement to preclinical development and initiation of associated IND-enabling studies under our discovery, development and licensing agreement," said Bob D. Brown, chief scientific officer at Dicerna. "These molecules represent the first targets under our collaboration with Lilly to address tissues outside the liver, highlighting the further expansion of our growing pipeline of RNAi therapeutics that address multiple tissues and cell types."

Dicerna and Lilly entered into a global licensing and research collaboration in 2018 focused on the discovery, development and commercialization of potential new therapies for cardiometabolic disease, neurodegenerative diseases and pain. Including the two targets highlighted on Friday, there are seven candidates in preclinical or clinical development.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

11-12-21 0839ET

Stocks mentioned in the article
ChangeLast1st jan.
DICERNA PHARMACEUTICALS, INC. 0.58% 38.22 End-of-day quote.0.00%
ELI LILLY AND COMPANY -2.22% 244.12 Delayed Quote.-11.62%
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 164 M - -
Net income 2020 -113 M - -
Net cash 2020 517 M - -
P/E ratio 2020 -14,5x
Yield 2020 -
Capitalization 2 986 M 2 986 M -
EV / Sales 2019 49,5x
EV / Sales 2020 6,92x
Nbr of Employees 302
Free-Float 92,6%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Bob D. Brown President
Douglas W. Pagßn Chief Financial Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
James B. Weissman Chief Operating Officer & Executive Vice President
Jamie Haney Director
Sector and Competitors